Mutant p53 expression in fallopian tube epithelium drives cell migration

作者: Suzanne M. Quartuccio , Subbulakshmi Karthikeyan , Sharon L. Eddie , Daniel D. Lantvit , Eoghainín Ó hAinmhire

DOI: 10.1002/IJC.29528

关键词: Fallopian tubeCarcinogenesisTransfectionCancer researchBiologySerous fluidOvarian cancerProgenitor cellPathologyCell migrationMutation

摘要: Ovarian cancer is the fifth leading cause of death among US women. Evidence supports hypothesis that high-grade serous ovarian cancers (HGSC) may originate in distal end fallopian tube. Although a heterogeneous disease, 96% HGSC contain mutations p53. In addition, "p53 signature," or overexpression p53 protein (usually associated with mutation), potential precursor lesion tube derived suggesting an essential role for mutation early tumorigenesis. To further clarify p53-mutation dependent effects on cells, murine oviductal epithelial cells (MOE) were stably transfected construct encoding R273H DNA binding domain p53, most common HGSC. Mutation was not sufficient to transform MOE but did significantly increase cell migration. A similar surface epithelium (MOSE), another progenitor cancer, nor change migration tissue specific mutation. Microarray data confirmed expression changes pro-migratory genes p53(R273H) compared parental which could be reversed by suppressing Slug expression. Combining KRAS(G12V) activation caused transformation into sarcomatoid carcinoma when xenografted nude mice. Elucidating will improve understanding at earliest stage transformation. This information can help develop chemopreventative strategies prevent accumulation additional and reverse progression signature" thereby, improving survival rates.

参考文章(49)
Cheryl A Sherman-Baust, Elisabetta Kuhn, Blanca L Valle, Ie-Ming Shih, Robert J Kurman, Tian-Li Wang, Tomokazu Amano, Minoru SH Ko, Ichiro Miyoshi, Yoshihiko Araki, Elin Lehrmann, Yongqing Zhang, Kevin G Becker, Patrice J Morin, A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. The Journal of Pathology. ,vol. 233, pp. 228- 237 ,(2014) , 10.1002/PATH.4353
Amir A. Jazaeri, Jennifer L. Bryant, Hong Park, Hui Li, Neetu Dahiya, Mark H. Stoler, James Stuart Ferriss, Anindya Dutta, Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma Neoplasia. ,vol. 13, pp. 899- 911 ,(2011) , 10.1593/NEO.11138
T-V Do, F Xiao, L E Bickel, A J Klein-Szanto, H B Pathak, X Hua, C Howe, S W O'Brien, M Maglaty, J A Ecsedy, S Litwin, E A Golemis, R J Schilder, A K Godwin, D C Connolly, Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion Oncogene. ,vol. 33, pp. 539- 549 ,(2014) , 10.1038/ONC.2012.632
C.-I. Hwang, A. Matoso, D. C. Corney, A. Flesken-Nikitin, S. Korner, W. Wang, C. Boccaccio, S. S. Thorgeirsson, P. M. Comoglio, H. Hermeking, A. Y. Nikitin, Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 108, pp. 14240- 14245 ,(2011) , 10.1073/PNAS.1017536108
S. D. Berman, E. Calo, A. S. Landman, P. S. Danielian, E. S. Miller, J. C. West, B. D. Fonhoue, A. Caron, R. Bronson, M. L. Bouxsein, S. Mukherjee, J. A. Lees, Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 11851- 11856 ,(2008) , 10.1073/PNAS.0805462105
Wen-Shu Wu, Stefan Heinrichs, Dong Xu, Sean P. Garrison, Gerard P. Zambetti, Jerry M. Adams, A. Thomas Look, Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma Cell. ,vol. 123, pp. 641- 653 ,(2005) , 10.1016/J.CELL.2005.09.029
Charles N. Landen, Michael J. Birrer, Anil K. Sood, Early Events in the Pathogenesis of Epithelial Ovarian Cancer Journal of Clinical Oncology. ,vol. 26, pp. 995- 1005 ,(2008) , 10.1200/JCO.2006.07.9970
Michael Zeisberg, Eric G. Neilson, Biomarkers for epithelial-mesenchymal transitions Journal of Clinical Investigation. ,vol. 119, pp. 1429- 1437 ,(2009) , 10.1172/JCI36183